Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Multi-Center placebo-controlled Double-Blind Randomized Trial
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2019
Price : $35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Myocardial infarction; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMBODY
- Sponsors Eli Lilly and Company
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.
- 02 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2018 Results published in the Diabetes Therapy